Scholarlink

Background <p>Gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs) such as imatinib. However, the development of drug resistance remains a critical clinical challenge, highlighting the urgent need for novel therapeutic agents with alternative mechanisms of action. This study aimed to identify and characterize new small molecules effective against imatinib-sensitive and resistant GISTs.</p> Methods <p>A library of 27 benzo[d]imidazo[2,1-b]thiazole derivatives was synthesized and screened for cytotoxicity against four GIST cell lines, including imatinib-sensitive (GIST-T1, GIST-882) and imatinib-resistant (GIST-48, GIST-48B) models. The most effective compound, MBT3T, was further evaluated for safety on healthy cells (PBMCs, fibroblasts) and mechanism of action using computational docking, immunofluorescence, and flow cytometry. Efficacy was validated both in 3D bioprinted tumor models and in vivo using zebrafish xenografts.</p> Results <p>MBT3T exhibited potent nanomolar cytotoxicity across all GIST cell lines while maintaining a favorable safety profile on healthy cells. Mechanistic studies revealed that MBT3T acts independently of the KIT signaling pathway, targeting tubulin at the colchicine-binding site. This interaction caused microtubule disassembly, leading to G2/M cell cycle arrest and caspase-mediated apoptosis. In in vivo zebrafish assays, MBT3T significantly reduced tumor growth in both imatinib-sensitive and resistant xenografts without inducing systemic toxicity.</p> Conclusion <p>We identified MBT3T as a novel, selective tubulin polymerization inhibitor. Its ability to bypass TKIs resistance mechanisms suggests it may represent a promising therapeutic candidate for the treatment of refractory GISTs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月21日

查看全文
  • Gloria Ravegnini,
  • Daniele Esposito,
  • Francesca Gorini,
  • Tainah Dorina Marforio,
  • Emma Coschina,
  • Eva Benuzzi,
  • Antonella Simone,
  • Ahmed Samaha,
  • Aldo Di Vito,
  • Martina Rossi,
  • Patrizia Hrelia,
  • Alessandra Locatelli,
  • Matteo Calvaresi,
  • Nicola Facchinello,
  • Rita Morigi,
  • Sabrina Angelini

摘要

Background

Gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs) such as imatinib. However, the development of drug resistance remains a critical clinical challenge, highlighting the urgent need for novel therapeutic agents with alternative mechanisms of action. This study aimed to identify and characterize new small molecules effective against imatinib-sensitive and resistant GISTs.

Methods

A library of 27 benzo[d]imidazo[2,1-b]thiazole derivatives was synthesized and screened for cytotoxicity against four GIST cell lines, including imatinib-sensitive (GIST-T1, GIST-882) and imatinib-resistant (GIST-48, GIST-48B) models. The most effective compound, MBT3T, was further evaluated for safety on healthy cells (PBMCs, fibroblasts) and mechanism of action using computational docking, immunofluorescence, and flow cytometry. Efficacy was validated both in 3D bioprinted tumor models and in vivo using zebrafish xenografts.

Results

MBT3T exhibited potent nanomolar cytotoxicity across all GIST cell lines while maintaining a favorable safety profile on healthy cells. Mechanistic studies revealed that MBT3T acts independently of the KIT signaling pathway, targeting tubulin at the colchicine-binding site. This interaction caused microtubule disassembly, leading to G2/M cell cycle arrest and caspase-mediated apoptosis. In in vivo zebrafish assays, MBT3T significantly reduced tumor growth in both imatinib-sensitive and resistant xenografts without inducing systemic toxicity.

Conclusion

We identified MBT3T as a novel, selective tubulin polymerization inhibitor. Its ability to bypass TKIs resistance mechanisms suggests it may represent a promising therapeutic candidate for the treatment of refractory GISTs.